Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centhaquine in Moderate to Severe ARDS
NCT05241067Phase 2Not yet recruiting
- Sponsor
- Pharmazz, Inc.
- Start
- May 2027
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of centhaquine in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Pharmazz, Inc. Primary endpoint: Improvement of PaO2/FiO2 ratio >=200 mmHg or relative increase by 50 mmHg from baseline at 3 days. Planned start May 2027; status: not yet recruiting.
02
Drugs
centhaquine
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05241067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241067.